Taiho Ventures, LLC — Full Portfolio

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

RHRichard Heyman(Chairman, Founder, Scientific Advisory Board)inCSCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)DPDominic Piscitelli(Chief Financial Officer)inPMPratik Multani(Chief Medical Officer)inJCJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsECEcoR1 CapitalNENew Enterprise Associates (NEA)NENextech InvestTHThe Column GroupVIViking GlobalOROrbiMed

Anavo Therapeutics is a biopharmaceutical company using its IGNITE platform to develop phosphatase-targeted allosteric modulators, addressing drug targets previously considered undruggable.

BiotechHealthtechLeiden, NL

Birgit Zech(CEO)in

Co-investorsBIBioqube VenturesINInkefM M Ventures

Breakpoint Therapeutics is a biotech company focused on oncology drug discovery and development centered on DNA damage response (DDR) mechanisms.

BiotechHealthtechMedical Devices

Daniel Speidel(Co-founder & Managing Director)Jon Hollick(Co-founder & Managing Director)

Co-investorsBIBiotechnology Value FundMEMedicxi

cellvie develops Therapeutic Mitochondria Transplantation technology and products for patients requiring mitochondrial treatment.

BiotechHealthtechLongevityMedical Devices

Co-investorsBEBeiersdorf Innovation Fund

Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.

AI & Machine LearningBiotechMedical Devices

Co-investorsABAbbVieMUMubadala CapitalVEVersant Ventures

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

RHRachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)MKMitchell Keegan(Chief Development Officer)inWLWilliam LaRochelle(Chief Scientific Officer)inSMStacy M. Plum(Chief Technology Officer)

Co-investorsSASanofi VenturesPFPfizer VenturesSASamsara BioCapitalCACanaan PartnersCOConnecticut InnovationsOUOUP (Osage University Partners)+6 more

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.

BiotechHealthtech

Co-investorsEPEpidarex CapitalOXOxford Science EnterprisesSOSound BioventuresM M Ventures

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

NTNenad Tomasevic(Founder)

BoardIvan Trifunovich(Director)John Wesley(Founder)

Board seatSASakae Asanuma· per SEC Form D

Co-investors8V8VCAIAisling CapitalHBHBM Healthcare InvestmentsHBHBM PartnersJAJacket River Capital PartnersMIMission Bay Capital+5 more

Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.

BiotechHealthtech

Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRMRichard Markus(Chief Medical Officer)inCTCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)

Co-investorsAIAisling CapitalDEDecheng CapitalDRDroia VenturesECEcoR1 CapitalFOForesite CapitalGVGV (Google Ventures)+4 more

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDWDmitri Wiederschain(Executive Officer)in

BoardACAlexandra Cantley(Director)inSakae Asanuma(Director)inBMBriggs Morrison(Executive Officer, Director, Promoter)inIMIrena Melnikova(Director)in

Co-investorsLILifelinkMPMPM BioImpactPFPfizer Venture InvestmentsBIBiotechnology Value FundMIMirae Asset Venture InvestmentPFPfizer Ventures+1 more

Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.

BiotechDigital Health

Co-investorsLALAVLILilly Asia VenturesMPMPM BioImpactSCSchooner Capital

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.

BiotechHealthtechCambridge, US

KMKevin Marks(Founder)in

Co-investorsGVGV (Google Ventures)NENextech InvestALAlexandria

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

ALAnn Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSBSamuel Bjork(Director)inACAlexandra Cantley(Director)inSMSeiji Miyahara(Director)in

Co-investorsAVAvego BioScience CapitalGVGV (Google Ventures)MIMission BiocapitalNONovartis Venture FundRORoche Venture FundSASamsara BioCapital+4 more

BiotechMedical DevicesNew Haven, US

Scott Phillips(Executive Officer)in

BoardTSTim Shannon(Manager)inLRLiam Ratcliffe(Manager)in

Co-investorsACAccess BiotechnologyCACanaan PartnersCOConnecticut InnovationsELElm Street VenturesFRFrazier Life SciencesRARA Capital+1 more

A research-intensive biopharmaceutical company that develops medicines and vaccines.

BiotechHealthtechSouth San Francisco, US

Luke Nathaniel Walker(Executive Officer)JEJulie Eastland(Executive Officer, Director)in

BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)

Co-investorsK2K2 HealthVenturesRIRidgeback CapitalARArix BioscienceLILilly Asia VenturesMPMPM BioImpactNENew Leaf Venture Partners+1 more

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

LJLeslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)SMSeiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)SGSteven Gillis(Director)in

Co-investorsARARCH Venture Partners5A5AM Ventures8V8VCATAtlas VenturePAPanacea VentureTATakeda Ventures

Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.

AI & Machine LearningBiotechMedical DevicesBoston, US

Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)MRMichael Rosbash, PhD(Founder & Advisor)RSRicha Saxena, PhD(Founder & Advisor)SSStuart Schreiber, PhD(Founder & Advisor)BSBrian Safina(President & Chief Executive Officer)in

Co-investorsARARCH Venture PartnersNENewpath Partners

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.

AI & Machine LearningBiotechMedical Devices

JBJoe Bolen(Chief Executive Officer)JBJoe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)CLCiaran Lawlor, Ph.D.(Chief Operating Officer)FNFrank Neumann, M.D., Ph.D.(Chief Medical Officer)SSSiva Sakhamuri(Chief Technology Officer)in

Co-investorsASAstellas Venture Management LLCMPMPM BioImpact

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsCACambridge Innovation CapitalFAFast Track InitiativeM M VenturesPFPfizer Venture InvestmentsSESeroba Life SciencesUTUTokyo Innovation Platform Co. Ltd.+3 more

Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.

AI & Machine LearningBiotechDeep TechCambridge, US

TKTuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)SCSamuel Cohen(Executive Director & Co-Founder)inG. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)inStephanie Torruella(Executive Officer)inPreet Makkar(Executive Officer)

Co-investorsNONorthpond VenturesLILifeforce CapitalMAMagnetic VenturesDODolby Family Ventures

Vertero develops therapies for neurodegenerative diseases by targeting causative mechanisms in the peripheral nervous system rather than addressing symptoms alone.

BiotechHealthtechMedical Devices

SMSarkis Mazmanian, PhD(Co-founder and Board Member)

Co-investorsAIAIFONOneVenturesSESeventure PartnersUTUTokyo Innovation Platform Co. Ltd.

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.

BiotechHealthtechMedical DevicesWatertown, US

Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)LELuke Evnin(Co-founder, Board member (Chairman))inDavid Cordo(Executive Officer)Alon Lazarus(Director)

BoardCWChristoph Westphal(Director)BMBriggs Morrison(Director)in

Co-investorsDCDC Investment PartnersK2K2 HealthVenturesLOLongwood FundMPMPM BioImpactRARA Capital

LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.

BiotechDeep Tech

TKToru Kankein

Co-investorsMCMC Healthcare VenturesUTUTokyo Innovation Platform Co. Ltd.